| scholarly article | Q13442814 |
| P50 | author | Marry M van den Heuvel-Eibrink | Q71498972 |
| P2093 | author name string | Andrew L Kung | |
| Scott A Armstrong | |||
| Tina N Davis | |||
| Christian M Zwaan | |||
| Joerg Faber | |||
| Renee Wright | |||
| Andrei V Krivtsov | |||
| Matthew C Stubbs | |||
| P2860 | cites work | The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9 | Q24317238 |
| Global and Hox-specific roles for the MLL1 methyltransferase | Q24529562 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells | Q24564511 | ||
| Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization | Q24603527 | ||
| Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice | Q24647139 | ||
| Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells | Q24670084 | ||
| 11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone | Q71844426 | ||
| Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study | Q72046351 | ||
| Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II | Q72656169 | ||
| Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission | Q72776739 | ||
| MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice | Q73086909 | ||
| Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality | Q73787705 | ||
| Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region | Q74267648 | ||
| Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1 | Q74355519 | ||
| Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases | Q74677600 | ||
| Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation | Q75447880 | ||
| Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny | Q77583284 | ||
| Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia | Q77628547 | ||
| Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia | Q79291743 | ||
| Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia | Q79777401 | ||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors | Q81772313 | ||
| Molecular classification of cancer: class discovery and class prediction by gene expression monitoring | Q27861072 | ||
| Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells | Q28215371 | ||
| The chromosome 4q21 gene (AF-4/FEL) is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia | Q28261549 | ||
| Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia | Q28273406 | ||
| Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells | Q28289099 | ||
| MLL targets SET domain methyltransferase activity to Hox gene promoters | Q28609771 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| GenePattern 2.0 | Q29614171 | ||
| A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen | Q29615061 | ||
| MLL translocations, histone modifications and leukaemia stem-cell development | Q29615368 | ||
| ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation | Q29618299 | ||
| Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. | Q33360320 | ||
| Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. | Q33761368 | ||
| Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia | Q33975157 | ||
| Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion | Q34106529 | ||
| NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice | Q34271495 | ||
| Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins | Q34405465 | ||
| Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. | Q34418792 | ||
| Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9 | Q35971222 | ||
| Enhancing and confirming the specificity of RNAi experiments | Q36575386 | ||
| H3K79 methylation profiles define murine and human MLL-AF4 leukemias | Q36991857 | ||
| MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia | Q38294261 | ||
| Protein arginine-methyltransferase-dependent oncogenesis | Q40077054 | ||
| Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. | Q40219637 | ||
| Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. | Q40252270 | ||
| Meis1-mediated apoptosis is caspase dependent and can be suppressed by coexpression of HoxA9 in murine and human cell lines. | Q40505091 | ||
| Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group | Q40742330 | ||
| The retroviral transduction of HOXC4 into human CD34(+) cells induces an in vitro expansion of clonogenic and early progenitors. | Q40879533 | ||
| Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo | Q41325322 | ||
| Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia | Q42150861 | ||
| Gefitinib induces myeloid differentiation of acute myeloid leukemia | Q42742416 | ||
| Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes. | Q43419606 | ||
| A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations | Q43684737 | ||
| Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification | Q44349388 | ||
| Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications | Q46853165 | ||
| Gene expression profiling of pediatric acute myelogenous leukemia | Q47266175 | ||
| Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. | Q51028737 | ||
| Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia. | Q55035943 | ||
| Induction of an interferon response by RNAi vectors in mammalian cells | Q58235166 | ||
| Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling | Q61910882 | ||
| Clinical characteristics of infant acute leukemia with or without 11q23 translocations | Q67937702 | ||
| Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome | Q70678937 | ||
| Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias | Q70905237 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 2375-2385 | |
| P577 | publication date | 2008-12-03 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | HOXA9 is required for survival in human MLL-rearranged acute leukemias | |
| P478 | volume | 113 |
| Q28298834 | A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis |
| Q48225815 | A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers. |
| Q91168625 | A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction |
| Q83395976 | Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model |
| Q42216959 | Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction |
| Q37461161 | BCOR regulates myeloid cell proliferation and differentiation |
| Q64063104 | Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis |
| Q34307027 | Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia |
| Q36056038 | CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. |
| Q38903073 | CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity |
| Q36206479 | Cell cycle control in acute myeloid leukemia. |
| Q37820053 | Cell lineage and cell death: Caenorhabditis elegans and cancer research |
| Q90854205 | Chromatin regulatory mechanisms and therapeutic opportunities in cancer |
| Q54442290 | Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia. |
| Q39091885 | Co-regulation of senescence-associated genes by oncogenic homeobox proteins and polycomb repressive complexes |
| Q42010591 | Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias |
| Q36658489 | Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic Targets |
| Q36783304 | Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML |
| Q84713544 | Cytogenetics and molecular genetics of acute lymphoblastic leukemia |
| Q37188783 | DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia |
| Q35083276 | DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis |
| Q42384637 | Dangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia |
| Q51817688 | Deciding the decider: Mef2c in hematopoiesis. |
| Q37031667 | Delineating the mixed lineage leukemia gene expression network in hematopoietic stem cells. |
| Q34726135 | Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology |
| Q37647046 | Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia |
| Q92856196 | Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia |
| Q42224444 | Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells. |
| Q34977743 | Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation |
| Q90678197 | ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia |
| Q38080336 | Engrailed homeobox transcription factors as potential markers and targets in cancer. |
| Q45754556 | Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia |
| Q37802749 | Epigenetic regulations in hematopoietic Hox code. |
| Q53218693 | Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease. |
| Q35685082 | Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells |
| Q37349410 | Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease |
| Q36892604 | Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants |
| Q39292054 | Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia |
| Q36392936 | Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes |
| Q37914244 | Glioma stem cell maintenance: the role of the microenvironment |
| Q64077434 | Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation |
| Q53325167 | Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? |
| Q38829055 | H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development |
| Q36932231 | HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. |
| Q52584615 | HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development. |
| Q38697273 | High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia. |
| Q33623126 | High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia |
| Q28299462 | High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event |
| Q27683539 | High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction |
| Q36585150 | Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia |
| Q34284318 | Hmga2 is a direct target gene of RUNX1 and regulates expansion of myeloid progenitors in mice. |
| Q48333821 | Hox5 Paralogous Genes Modulate Th2 Cell Function during Chronic Allergic Inflammation via Regulation of Gata3. |
| Q64998065 | HoxA9 binds and represses the Cebpa +8 kb enhancer. |
| Q42770287 | HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia |
| Q34551218 | Hoxa9 transduction induces hematopoietic stem and progenitor cell activity through direct down-regulation of geminin protein |
| Q37163718 | Hoxb8 regulates expression of microRNAs to control cell death and differentiation. |
| Q55555549 | Human MLL-AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish. |
| Q35589633 | Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential |
| Q36733776 | Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia |
| Q42385858 | Impact of homeobox genes in gastrointestinal cancer |
| Q52597914 | Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. |
| Q39062437 | Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML. |
| Q34022420 | Interaction of retinoic acid and scl controls primitive blood development |
| Q37032161 | Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia |
| Q45873757 | LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis |
| Q34275371 | Leukaemogenesis: more than mutant genes |
| Q102075479 | Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model |
| Q54416763 | Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. |
| Q30313615 | Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia |
| Q94600092 | MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia |
| Q35450566 | MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia |
| Q35788362 | MLL fusions: pathways to leukemia |
| Q36115756 | MLL leukemia induction by genome editing of human CD34+ hematopoietic cells |
| Q33473001 | MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures |
| Q36618536 | MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. |
| Q45800076 | MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. |
| Q37633585 | MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. |
| Q98153675 | MLLT10 rearranged acute leukemia: incidence, prognosis and possible therapeutic strategies |
| Q41370213 | Maintenance of leukemic cell identity by the activity of the Polycomb complex PRC1 in mice. |
| Q38190545 | Mechanisms of mixed-lineage leukemia |
| Q38029260 | Menin as a hub controlling mixed lineage leukemia |
| Q36437006 | MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia |
| Q91452449 | MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells |
| Q101564396 | Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes |
| Q38100107 | Mixed lineage leukemia protein in normal and leukemic stem cells |
| Q37710708 | Mixed lineage leukemia: roles in human malignancies and potential therapy |
| Q38161393 | Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis |
| Q36290242 | Molecular genetics of B-precursor acute lymphoblastic leukemia |
| Q39127003 | Mouse models of MLL leukemia: recapitulating the human disease |
| Q33987248 | Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis |
| Q61136622 | Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis |
| Q38084093 | Myocyte enhancer factor 2C in hematopoiesis and leukemia |
| Q64078767 | NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis |
| Q46550111 | NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis |
| Q55039489 | PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia. |
| Q48092198 | PARP inhibitors: a treatment option for AML? |
| Q36735211 | PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease |
| Q36628305 | PBX3 is an important cofactor of HOXA9 in leukemogenesis |
| Q48272949 | PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia |
| Q38700890 | PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation. |
| Q37970679 | Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia |
| Q92151828 | Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia |
| Q47863498 | Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations. |
| Q35600743 | Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond |
| Q57810481 | Polycomb complexes in normal and malignant hematopoiesis |
| Q41321988 | Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature. |
| Q34752160 | Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes |
| Q38003359 | Recent advances in acute myeloid leukemia stem cell biology |
| Q93005015 | Redistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes |
| Q42270757 | Regulation of MEIS1 by distal enhancer elements in acute leukemia. |
| Q34310186 | Requirement for CDK6 in MLL-rearranged acute myeloid leukemia |
| Q96765845 | Requirement for LIM kinases in acute myeloid leukemia |
| Q39856628 | Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia |
| Q28082027 | Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets |
| Q28273918 | SALL4 is a key transcription regulator in normal human hematopoiesis |
| Q90317043 | SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation |
| Q38908846 | Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. |
| Q33716402 | Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. |
| Q35045315 | Selective targeting of histone methylation |
| Q48518410 | Silencing of HMGA2 reverses retardance of cell differentiation in human myeloid leukaemia |
| Q49216080 | Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia |
| Q38817669 | Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors |
| Q37031819 | TET1 plays an essential oncogenic role in MLL-rearranged leukemia |
| Q42182795 | TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia |
| Q36989223 | Targeted drug discovery for pediatric leukemia |
| Q36786792 | Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4 |
| Q93382193 | Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia |
| Q91865401 | Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia |
| Q28282573 | Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex |
| Q36331291 | Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia |
| Q38739798 | The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. |
| Q37722452 | The Hox genes and their roles in oncogenesis. |
| Q92702410 | The Role of the HOXA Gene Family in Acute Myeloid Leukemia |
| Q36547690 | The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. |
| Q39460854 | The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9. |
| Q37797944 | The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network |
| Q40560744 | The next new target in leukemia: The embryonic stem cell gene SALL4. |
| Q92802709 | The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies |
| Q35738628 | The pathological role and prognostic impact of miR-181 in acute myeloid leukemia |
| Q38065068 | The role of HOX genes in normal hematopoiesis and acute leukemia. |
| Q38129726 | The role of miR-150 in normal and malignant hematopoiesis |
| Q34033164 | The role of mutations in epigenetic regulators in myeloid malignancies |
| Q52840547 | The roles of HOXB7 in promoting migration, invasion, and anti-apoptosis in gastric cancer. |
| Q36892595 | The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia |
| Q37410557 | Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity |
| Q37863271 | Transcriptional and epigenetic networks in haematological malignancy |
| Q51890625 | Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia. |
| Q47696737 | Transcriptional memory of cells of origin overrides β-catenin requirement of MLL cancer stem cells |
| Q92337654 | Transcriptional networks in acute myeloid leukemia |
| Q58492911 | Translokationen des MLL-Gens |
| Q43144356 | Trithorax and polycomb cooperation in MLL fusion acute leukemia |
| Q47068976 | Trithorax, Hox, and TALE-class homeodomain proteins ensure cell survival through repression of the BH3-only gene egl-1. |
| Q58692793 | Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches |
| Q36101066 | Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia |
| Q35849255 | Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. |
| Q42265722 | ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. |
| Q36445463 | miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia |
| Q37010564 | miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. |
| Q37504409 | p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia |
Search more.